Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

16
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
16
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.4K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

16
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
16
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

21
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
21
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

3
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
3
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.5K
The pathophysiology of pneumonia involves the following steps:
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a breath-holding test as a screening test for exercise-induced hypoxemia in chronic respiratory diseases.

Chronic respiratory disease·2021
Same author

Pathological and clinical relevance of selective recruitment of Langerhans cells in the respiratory bronchioles of smokers.

Respiratory investigation·2021
Same author

Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.

International journal of clinical oncology·2020
Same author

Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.

Laboratory investigation; a journal of technical methods and pathology·2020
Same author

Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.

Laboratory investigation; a journal of technical methods and pathology·2019
Same author

Asthma exacerbations in patients with asthma and rhinitis: Factors associated with asthma exacerbation and its effect on QOL in patients with asthma and rhinitis.

Allergology international : official journal of the Japanese Society of Allergology·2019

Related Experiment Video

Updated: Apr 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Cisplatin-induced eosinophilic pneumonia.

Hideharu Ideguchi1, Keisuke Kojima1, Susumu Hirosako1

  • 1Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Case Reports in Pulmonology
|December 6, 2014
PubMed
Summary

Cisplatin, a chemotherapy drug, can cause a rare lung condition called eosinophilic pneumonia. This case highlights the importance of recognizing this side effect for prompt treatment with corticosteroids.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

2.0K

Related Experiment Videos

Last Updated: Apr 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

2.0K

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Esophageal cancer patients undergoing chemotherapy may experience respiratory complications.
  • Chemotherapy regimens, including cisplatin, docetaxel, and fluorouracil, are associated with various adverse effects.
  • Eosinophilic pneumonia is a rare but serious condition that can be drug-induced.

Purpose of the Study:

  • To report the first case of cisplatin-induced eosinophilic pneumonia.
  • To highlight the diagnostic challenges and successful treatment of this rare adverse drug reaction.

Main Methods:

  • A 67-year-old male patient with esophageal cancer presented with dyspnea and hypoxemia.
  • Diagnostic workup included chest CT, bronchoalveolar lavage, and peripheral blood eosinophil counts.
  • Drug-induced lymphocyte stimulation test (DLST) was performed for cisplatin.

Main Results:

  • Chest CT showed bilateral ground-glass opacity.
  • Bronchoalveolar lavage revealed increased eosinophils.
  • Peripheral blood eosinophilia was observed transiently after chemotherapy, and DLST for cisplatin was positive.
  • Corticosteroid therapy resulted in effective symptom resolution.

Conclusions:

  • Cisplatin can induce eosinophilic pneumonia, a rare adverse effect.
  • Prompt diagnosis and corticosteroid treatment are crucial for managing cisplatin-induced eosinophilic pneumonia.
  • This case underscores the need for vigilance in identifying drug-induced lung injury in cancer patients.